,

Ovagen (Glu-Asp-Leu) | 20mg/2ml

$79.00

What is Ovagen (Glu-Asp-Leu)?

Ovagen is a synthetic tripeptide composed of glutamic acid, aspartic acid, and leucine, developed to support ovarian function and regulate female reproductive health. It is designed to promote hormone production, improve follicular dynamics, and assist in restoring reproductive balance.

By acting on ovarian cell activity and hormonal signaling, Ovagen is being studied in the fields of fertility optimization, hormonal regulation, and reproductive aging. Its potential applications extend from enhancing ovulation to supporting ovarian recovery after medical interventions.

How Does Ovagen (Glu-Asp-Leu) Work?

Ovagen works by influencing core processes within the ovaries and endocrine system:

 

  • Ovarian Cell Stimulation: Ovagen activates key ovarian cells such as granulosa and theca cells, which are responsible for hormone production and follicular maturation—both essential for ovulation and reproductive readiness.

 

  • Hormonal Regulation: Ovagen helps regulate estrogen and progesterone levels, supporting menstrual cycle consistency and preparing the endometrium for possible conception.
  • Restoring Reproductive Balance: In conditions of hormonal imbalance or ovarian suppression, Ovagen may help restore physiological function by enhancing the natural hormone feedback loop and improving ovarian responsiveness.
  • Addressing Functional Decline: The peptide may counteract early signs of ovarian aging or stress-induced dysfunction by promoting healthy follicle growth and preserving ovarian reserve.

Research on Ovagen (Glu-Asp-Leu)

Scientific investigations into Ovagen focus on its effects in fertility preservation and reproductive system support:

Follicular Development and Egg Quality

Studies indicate Ovagen may improve follicle maturation and the surrounding cellular environment, which can influence oocyte quality and reproductive potential, particularly in women with suboptimal ovarian response.

Hormonal Secretion Pathways

=Ovagen is being studied for its influence on the hypothalamic-pituitary-ovarian axis and its ability to encourage balanced secretion of reproductive hormones critical for ovulation and cycle regulation.

Fertility Preservation in Aging

By supporting ovarian activity and reducing atresia in follicles, Ovagen may help delay age-related reproductive decline, making it a potential tool in extending fertility windows.

Support in Premature Ovarian Insufficiency (POI)

Research is exploring its ability to reinitiate hormone production and ovarian responsiveness in cases of early ovarian failure, offering hope for functional recovery in select patients.

Ovagen (Glu-Asp-Leu) – Structural and Molecular Properties

Ovagen is a synthetic tripeptide consisting of three amino acids: Glutamic acid (Glu), Aspartic acid (Asp), and Leucine (Leu). This peptide is designed to support immune modulation, tissue regeneration, and cellular health by interacting with specific biological systems, particularly in areas related to vascular health, tissue repair, and inflammation control.

Compact and Stable Peptide Structure

The tripeptide structure of Ovagen is compact, consisting of three essential amino acids. Its short length makes it efficient and stable, while still maintaining the biological activity necessary for targeted action. The peptide’s stability is crucial for its effectiveness, as it reduces the chances of enzymatic degradation and allows it to remain active in the body for longer periods, especially when targeted to tissues in need of regeneration or repair.

Enhanced Bioavailability

The small molecular size of Ovagen enhances its bioavailability, allowing for efficient absorption and targeted delivery to the musculoskeletal system and immune tissues. Its compact structure enables it to penetrate tissues effectively, facilitating its role in promoting cellular regeneration, immune system regulation, and recovery from injuries or inflammation. The peptide is designed to reach damaged tissues more effectively than larger, more complex proteins or peptides.

Low Immunogenicity

The relatively simple and short peptide chain of Ovagen results in low immunogenicity, meaning it is less likely to cause immune system reactions or allergic responses. This property makes Ovagen a promising candidate for long-term clinical use, as it minimizes the risk of adverse immune reactions. This also makes Ovagen suitable for applications where sustained treatment is necessary, such as chronic inflammatory diseases and musculoskeletal rehabilitation.

History and Development of Ovagen (Glu-Asp-Leu)

Ovagen was developed through research on short peptides capable of influencing reproductive physiology and hormonal pathways. Its design aimed to offer a non-hormonal support tool for enhancing ovarian activity and fertility potential in women with reproductive challenges.

Current investigations are focused on its use in reproductive medicine, including applications in PCOS, perimenopause, and fertility preservation strategies. Ovagen is emerging as a promising candidate in the broader field of bioregulatory peptide therapy for women’s health.

Benefits and Potential Applications of Ovagen (Glu-Asp-Leu)

Ovagen’s potential benefits span various reproductive and hormonal health areas:

 

  • Polycystic Ovary Syndrome (PCOS) Management: Ovagen may aid in restoring ovulatory cycles and improving follicle development in women with PCOS by modulating hormone output and follicular responsiveness.

 

  • Menstrual Regularity: Its influence on estrogen-progesterone balance can support more predictable cycles in women experiencing irregular menstruation due to hormonal disruptions.
  • Post-Treatment Recovery: After exposure to medical treatments such as chemotherapy or infections that impair ovarian function, Ovagen may help reinitiate hormone production and follicular activity.
  • Hormonal Balance Optimization: For women with subtle hormonal imbalances, Ovagen supports the natural rhythm of the endocrine system, improving the conditions necessary for conception and reproductive stability.

Possible Side Effects of Ovagen (Glu-Asp-Leu)

Ovagen (Glu-Asp-Leu) has been studied for its fertility-enhancing, ovarian health-supporting, and hormonal-regulating effects. It is generally considered well-tolerated in experimental settings, but as with any bioactive peptide, some individuals may experience mild, transient side effects. These effects are typically dose-dependent and can vary based on individual sensitivity or underlying conditions.

 

  • Mild Hormonal Fluctuations: Due to Ovagen’s role in stimulating hormonal production, some users may experience temporary hormonal fluctuations as the body adjusts to enhanced estrogen and progesterone levels. This may manifest as mild mood changes, irregular spotting, or temporary changes in menstrual cycle length, particularly during the initial stages of use. These effects usually resolve as the body adapts to the peptide’s influence on hormone production.

 

  • Ovarian Sensitivity or Mild Discomfort: Ovagen’s action on follicular development may result in temporary ovarian sensitivity or mild discomfort in some women. This could feel like slight pelvic discomfort or fullness during follicular growth. Such sensations are typically mild and should subside as the body adjusts to the stimulation of the ovarian cells.
  • Headaches or Dizziness: In some individuals, hormonal adjustments and increased circulation may lead to mild headaches or dizziness. These symptoms are generally short-lived and may occur when the body is adjusting to Ovagen’s effects on ovarian and hormonal functions.
  • Fatigue or Lethargy: Some users might report mild fatigue or lethargy, especially during the first few weeks of treatment. This is thought to be a result of increased metabolic activity and hormonal changes associated with the peptide’s effects on ovarian health. Such effects usually dissipate as the body adapts to the therapy.

These side effects are generally mild, short-lived, and dose-dependent. No serious or long-term adverse reactions have been reported in clinical trials or preclinical research.

Ovagen | Pre-Mixed Pen – Unit and Microgram (mcg), Milligram (mg) Analysis

A 20 mg Ovagen pen contains 200 units, with each unit equivalent to 100 micrograms. Example dosing scheme:

  • 1 unit = 100mcg
  • 10 units = 1mg
  • 20 units = 2mg
  • 30 units = 3mg

These parameters allow for precise dosing and flexibility in research applications.

 

Guaranteed Safe Checkout
Shopping Cart
error: Content is protected !!
Ovagen (Glu-Asp-Leu) | 20mg/2mlOvagen (Glu-Asp-Leu) | 20mg/2ml
$79.00
Scroll to Top